Predicting treatment response based on RNA expression in large datasets

Research output: Contribution to journalArticle

Abstract

PD-L1 expression levels derived from >16,000 samples guided the selection of tumor types likely to benefit from pembrolizuamb monotherapy in clinical trials. Although not fail-proof, FDA approvals for most of the prioritized indications speak to the power of RNA expression profiling and the value of large genomic datasets.

Original languageEnglish (US)
Pages (from-to)1443-1445
Number of pages3
JournalClinical Cancer Research
Volume25
Issue number5
DOIs
StatePublished - Mar 1 2019

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Predicting treatment response based on RNA expression in large datasets'. Together they form a unique fingerprint.

  • Cite this